BRPI0618577A8 - Usos de rituximab - Google Patents

Usos de rituximab

Info

Publication number
BRPI0618577A8
BRPI0618577A8 BRPI0618577A BRPI0618577A BRPI0618577A8 BR PI0618577 A8 BRPI0618577 A8 BR PI0618577A8 BR PI0618577 A BRPI0618577 A BR PI0618577A BR PI0618577 A BRPI0618577 A BR PI0618577A BR PI0618577 A8 BRPI0618577 A8 BR PI0618577A8
Authority
BR
Brazil
Prior art keywords
rituximab
methods
joint damage
subject
cd2o
Prior art date
Application number
BRPI0618577A
Other languages
English (en)
Inventor
Totoritis Mark
Mark Shaw Timothy
Agarwal Sunil
Yocum David
Kelman Ariella
Original Assignee
Genentech Inc
Hoffmann La Roche
Biogen Idec Inc
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37807774&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0618577(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc, Hoffmann La Roche, Biogen Idec Inc, Biogen Inc filed Critical Genentech Inc
Publication of BRPI0618577A2 publication Critical patent/BRPI0618577A2/pt
Publication of BRPI0618577A8 publication Critical patent/BRPI0618577A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

USOS DE RITUXIMAB. A presente invenção refere-se a métodos de tratamento de lesão articular em um indivíduo elegível para tratamento, que envolvem a administração de um antagonista que se liga a um marcador de superfície das células B, tais como o anticorpo CD2O, ao indivíduo, em uma quantidade eficaz para tornar mais lenta a progressão da lesão articular, como medida por radiografia. São ainda fornecidos artigos manufaturados úteis para tais métodos.
BRPI0618577A 2005-11-15 2006-11-14 Usos de rituximab BRPI0618577A8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US73729105P 2005-11-15 2005-11-15
US60/737,291 2005-11-15
US86446306P 2006-11-06 2006-11-06
US60/864,463 2006-11-06
PCT/US2006/044290 WO2007059188A1 (en) 2005-11-15 2006-11-14 Method for treating joint damage

Publications (2)

Publication Number Publication Date
BRPI0618577A2 BRPI0618577A2 (pt) 2011-09-06
BRPI0618577A8 true BRPI0618577A8 (pt) 2016-12-20

Family

ID=37807774

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0618577A BRPI0618577A8 (pt) 2005-11-15 2006-11-14 Usos de rituximab

Country Status (30)

Country Link
US (5) US20090238762A1 (pt)
EP (1) EP1951304B1 (pt)
JP (4) JP2009515979A (pt)
KR (5) KR20190009425A (pt)
CN (2) CN103212070A (pt)
AR (1) AR058838A1 (pt)
AU (1) AU2006315498B2 (pt)
BR (1) BRPI0618577A8 (pt)
CA (2) CA2627886C (pt)
CR (1) CR10005A (pt)
DK (1) DK1951304T3 (pt)
EC (1) ECSP088514A (pt)
ES (1) ES2526616T3 (pt)
HK (2) HK1123209A1 (pt)
HR (1) HRP20150018T1 (pt)
IL (1) IL191118B (pt)
MA (1) MA30047B1 (pt)
MX (1) MX2008006113A (pt)
MY (2) MY149159A (pt)
NO (1) NO20082658L (pt)
NZ (1) NZ567709A (pt)
PL (1) PL1951304T3 (pt)
PT (1) PT1951304E (pt)
RS (1) RS53767B1 (pt)
RU (1) RU2457860C2 (pt)
SI (1) SI1951304T1 (pt)
TW (1) TWI380826B (pt)
UA (1) UA94726C2 (pt)
WO (1) WO2007059188A1 (pt)
ZA (1) ZA200804288B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0201009A2 (en) 1999-05-07 2002-07-29 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
ES2557768T3 (es) 1999-06-01 2016-01-28 Biogen Ma Inc. Un anticuerpo monoclonal bloqueante frente a VLA-1 y su uso para el tratamiento de trastornos inflamatorios
WO2002083854A2 (en) 2001-04-13 2002-10-24 Biogen, Inc. Antibodies to vla-1
EP2062916A3 (en) * 2003-04-09 2009-08-19 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitor
ME01775B (me) 2003-11-05 2011-02-28 Glycart Biotechnology Ag Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
CN101494978A (zh) * 2006-05-25 2009-07-29 比奥根艾迪克Ma公司 治疗中风的方法
AU2013202392B2 (en) * 2006-12-20 2016-02-25 Mmrglobal, Inc. Antibodies and methods for making and using them
EP2716657A3 (en) 2006-12-20 2014-10-08 Mmrglobal, Inc. Antibodies and methods for making and using them
GB0718684D0 (en) * 2007-09-24 2007-10-31 Roche Products Ltd Treatment method
PL2219675T3 (pl) 2007-11-12 2014-04-30 Ares Trading Sa Formulacja dla białek fuzyjnych TACI-immunoglobulina
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
EP2443573A4 (en) * 2009-06-19 2016-09-07 Optuminsight Inc SYSTEM AND METHOD FOR GENERATING ATTRIBUTE-CONTROLLED TEMPORAL CLUSTERING
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
KR20180129991A (ko) 2010-11-05 2018-12-05 노파르티스 아게 Ｉｌ-１７ 길항제를 사용한 류마티스성 관절염의 치료 방법
JP2014505703A (ja) * 2011-02-03 2014-03-06 サンタラス， インコーポレイテッド 対象の選択および治療
MX370199B (es) 2012-02-16 2019-12-05 Santarus Inc Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a).
WO2013142336A1 (en) * 2012-03-21 2013-09-26 Miller Leonard B Combination therapy to improve joint, tendon, and ligament healing
WO2014107566A1 (en) 2013-01-04 2014-07-10 Massachusetts Institute Of Technology Surface binding of nanoparticle based drug delivery to tissue
US9782476B2 (en) 2013-09-06 2017-10-10 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
CN106573971A (zh) 2014-05-27 2017-04-19 中央研究院 抗cd20醣抗体及其用途
JP7093612B2 (ja) 2014-05-27 2022-06-30 アカデミア シニカ Ｂａｃｔｅｒｏｉｄｅｓ由来のフコシダーゼおよびそれを使用する方法
JP7062361B2 (ja) 2014-05-27 2022-05-06 アカデミア シニカ 抗ｈｅｒ２糖操作抗体群およびその使用
JP7063538B2 (ja) 2014-05-28 2022-05-09 アカデミア シニカ 抗ＴＮＦα糖操作抗体群およびその使用
US10538592B2 (en) 2016-08-22 2020-01-21 Cho Pharma, Inc. Antibodies, binding fragments, and methods of use
RU2724469C2 (ru) 2018-10-31 2020-06-23 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с cd20
US20230211024A1 (en) * 2019-12-05 2023-07-06 Imaginab, Inc. Methods of imaging using multiple imaging agents
RU2749852C1 (ru) * 2020-06-25 2021-06-17 федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Западный государственный медицинский университет им. И.И. Мечникова" Министерства здравоохранения Российской Федерации Способ лечения пациентов после травматических повреждений вращательной манжеты плечевого сустава
CN112669929B (zh) * 2020-12-30 2021-08-03 深圳大学 克罗恩病英夫利昔单抗药效预测方法及终端设备
RU2748130C1 (ru) * 2021-01-19 2021-05-19 Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр реабилитации и курортологии» Министерства здравоохранения Российской Федерации (ФГБУ «НМИЦ РК» Минздрава России) Способ отбора пациентов для экстраполяционной роботизированной механотерапии при повреждениях вращательной манжеты плеча

Family Cites Families (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IL47062A (en) 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4665077A (en) 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5506126A (en) 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
HUT53672A (en) 1988-02-25 1990-11-28 Gen Hospital Corp Quick immunoselective cloning process
IL85746A (en) 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
US4861579A (en) 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
WO1990008187A1 (en) 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2064077C (en) 1989-07-19 2002-03-12 Arthur A. Vandenbark T cell receptor peptides as therapeutics for autoimmune and malignant disease
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
EP0625200B1 (en) 1992-02-06 2005-05-11 Chiron Corporation Biosynthetic binding protein for cancer marker
ATE244763T1 (de) 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
DE69322860T2 (de) 1992-04-03 1999-07-01 Genentech, Inc., South San Francisco, Calif. Antikörper gegen alpha v beta 3 integrin
CA2138366C (en) * 1992-06-30 1998-09-22 Kristine Hovancik Methods for the treatment of arthritis using phosphonates and nsaids
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DK0669836T3 (da) 1992-11-13 1996-10-14 Idec Pharma Corp Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
US5417972A (en) 1993-08-02 1995-05-23 The Board Of Trustees Of The Leland Stanford Junior University Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5637597A (en) 1993-10-21 1997-06-10 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives for inhibiting production of interleukin-8
WO1996004925A1 (en) 1994-08-12 1996-02-22 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
ATE267610T1 (de) 1996-03-20 2004-06-15 Immunomedics Inc Glykosylierte igg antikörper
US20010056066A1 (en) 1996-07-26 2001-12-27 Smithkline Beecham Corporation Method of treating immune cell mediated systemic diseases
CA2665133A1 (en) 1996-10-25 1998-05-07 Human Genome Sciences, Inc. Neutrokine .alpha.
WO1998027114A2 (en) 1996-12-17 1998-06-25 Schering Corporation Mammalian cell surface antigens; related reagents
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
CA2232743A1 (en) 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
EP0999853B1 (en) 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
DE69830315T2 (de) 1997-06-24 2006-02-02 Genentech Inc., San Francisco Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
AU8296098A (en) 1997-07-08 1999-02-08 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
CA2303424A1 (en) 1997-09-12 1999-03-18 Jurg Tschopp Kay - a novel immune system protein
ATE419009T1 (de) 1997-10-31 2009-01-15 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
WO1999033980A2 (en) 1997-12-30 1999-07-08 Chiron Corporation Members of tnf and tnfr families
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
ES2532910T3 (es) 1998-04-02 2015-04-01 Genentech, Inc. Variantes de anticuerpos y fragmentos de los mismos
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
GB9811969D0 (en) 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
NZ528199A (en) 1998-08-11 2005-06-24 Idec Pharma Corp Combination therapies for B-cell lyphomas comprising administration of anti-CD20 antibody
DE19836659A1 (de) 1998-08-13 2000-02-17 Hoechst Schering Agrevo Gmbh Herbizide Mittel für tolerante oder resistente Baumwollkulturen
US6196979B1 (en) 1998-08-24 2001-03-06 Burstein Technologies, Inc. Cassette and applicator for biological and chemical sample collection
US7029652B2 (en) * 1998-09-16 2006-04-18 The Regents Of The University Of California Method of treating tumors
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
US6224866B1 (en) 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
WO2000027433A1 (en) 1998-11-09 2000-05-18 Idec Pharmaceuticals Corporation Chimeric anti-cd20 antibody treatment of patients receiving bmt or pbsc transplants
PT1616572E (pt) 1998-11-09 2010-11-11 Biogen Idec Inc Anticorpo quimérico anti-cd20, rituxan, para utilização no tratamento de leucemia linfocítica crónica
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
GB9828074D0 (en) 1998-12-18 1999-02-17 Glaxo Group Ltd Therapeutically useful compounds
EP1141274B2 (en) 1999-01-07 2014-11-12 ZymoGenetics, Inc. Soluble receptor br43x2 and methods of using them for therapy
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
US6383276B1 (en) 1999-03-12 2002-05-07 Fuji Photo Film Co., Ltd. Azomethine compound and oily magenta ink
US6565927B1 (en) 1999-04-07 2003-05-20 Board Of Trustees Of Michigan State University Method for treatment of surfaces with ultraviolet light
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
WO2000068378A1 (en) 1999-05-06 2000-11-16 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
HUP0201009A2 (en) 1999-05-07 2002-07-29 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
US7074403B1 (en) 1999-06-09 2006-07-11 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target B-cells
ITMI991299A1 (it) 1999-06-11 2000-12-11 Consiglio Nazionale Ricerche Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
DE19930748C2 (de) 1999-07-02 2001-05-17 Infineon Technologies Ag Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip
CN1373672A (zh) 1999-07-12 2002-10-09 杰南技术公司 应用结合cd20的拮抗剂阻断对外来抗原的免疫应答
US6451284B1 (en) 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
JP2003513012A (ja) 1999-08-11 2003-04-08 アイデック ファーマスーティカルズ コーポレイション 抗ｃｄ２０抗体による骨髄病変を伴う非ホジキンリンパ腫を有する患者の治療
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
EP1210425B2 (en) 1999-08-17 2015-06-17 Biogen MA Inc. Baff receptor (bcma), an immunoregulatory agent
WO2001013945A1 (en) 1999-08-23 2001-03-01 Biocrystal Ltd. Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis
CA2388245C (en) 1999-10-19 2012-01-10 Tatsuya Ogawa The use of serum-free adapted rat cells for producing heterologous polypeptides
RU2305561C2 (ru) 1999-11-08 2007-09-10 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием антител против cd40l в комбинации с антителами против cd20 и/или химиотерапией и лучевой терапией
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US20020028178A1 (en) 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US7074408B2 (en) 2000-02-25 2006-07-11 Immunex Corporation Use of integrin antagonists to inhibit angiogenesis
AU2001247737A1 (en) 2000-03-24 2001-10-08 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma using a combination of an antibodyto cd20 and interleuking-2
US20030185796A1 (en) 2000-03-24 2003-10-02 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma
CN1981868A (zh) 2000-03-31 2007-06-20 拜奥根Idec公司 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用
EP1272647B1 (en) 2000-04-11 2014-11-12 Genentech, Inc. Multivalent antibodies and uses therefor
JP2003531141A (ja) 2000-04-17 2003-10-21 セルテック アール アンド ディ リミテッド エナミン誘導体
JP2003531178A (ja) 2000-04-25 2003-10-21 アイデック ファーマスーティカルズ コーポレイション 中枢神経系リンパ腫治療用のリツキシマブのクモ膜下投与
EP2052742A1 (en) 2000-06-20 2009-04-29 Biogen Idec Inc. Treatment of B-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combination
SI1296714T1 (sl) 2000-06-22 2010-01-29 S For Entpr University Of Iowa Kombinacija CpG-ja in protiteles, usmerjenih proti CD19, CD20, CD22 ali CD40 za zdravljenje ali preprečevanje raka
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
KR20040023565A (ko) * 2000-09-18 2004-03-18 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 고갈/면역조절 항체 조합을 이용한 자가면역질환의 치료를 위한 조합 요법
DE60124573T2 (de) 2000-09-29 2007-06-21 Ajinomoto Co., Inc. Neue phenylalanin-derivate
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
AU2002213357A1 (en) 2000-10-20 2002-05-06 Idec Pharmaceuticals Corporation Variant igg3 rituxan r and therapeutic use thereof
IL156618A0 (en) 2000-12-28 2004-01-04 Altus Biologics Inc Crystals of whole antibodies and fragments thereof, methods for the preparation thereof and diagnostic kits utilizing the same
JP2004525620A (ja) 2001-01-17 2004-08-26 トルビオン・ファーマシューティカルズ・インコーポレイテッド 結合ドメイン−免疫グロブリン融合タンパク質
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
IL157142A0 (en) 2001-01-29 2004-02-08 Idec Pharma Corp Modified antibodies and methods of use
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US20030103971A1 (en) 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
WO2002078766A2 (en) 2001-04-02 2002-10-10 Genentech, Inc. Combination therapy
US20030003097A1 (en) 2001-04-02 2003-01-02 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with GnTIII
WO2003061694A1 (en) 2001-05-10 2003-07-31 Seattle Genetics, Inc. Immunosuppression of the humoral immune response by anti-cd20 antibodies
ES2387546T3 (es) 2001-05-11 2012-09-25 Amgen Inc. Péptidos y moléculas relacionadas que se unen a TALL-1
EP1404366A4 (en) 2001-06-14 2006-06-07 Intermune Inc COMBINED THERAPY USING INTERFERON GAMMA AND SPECIFIC B-CELL ANTIBODIES
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
JP4164871B2 (ja) 2001-07-26 2008-10-15 味の素株式会社 新規フェニルプロピオン酸誘導体
HUP0500992A3 (en) 2001-08-03 2007-11-28 Genentech Inc Tacis and br3 polypeptides and uses thereof
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES
EP1438583B1 (en) 2001-09-20 2009-09-16 Board of Regents, The University of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays
GB2380127A (en) 2001-09-26 2003-04-02 Isis Innovation Treatment of chronic joint inflammation
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
JP2005538034A (ja) 2001-12-07 2005-12-15 カイロン コーポレイション 非ホジキンリンパ腫の治療方法
EP1454898A4 (en) 2001-12-13 2006-12-13 Ajinomoto Kk NEW PHENYL ALANIDE DERIVATIVES
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
WO2003068822A2 (en) 2002-02-13 2003-08-21 Micromet Ag De-immunized (poly)peptide constructs
CA2476166C (en) 2002-02-14 2011-11-15 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
JP4470219B2 (ja) 2002-02-20 2010-06-02 味の素株式会社 新規フェニルアラニン誘導体
US20030202975A1 (en) 2002-02-21 2003-10-30 Tedder Thomas F. Reagents and treatment methods for autoimmune diseases
US20030180292A1 (en) 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
WO2003084569A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition anticorps
WO2003084570A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition d'anticorps appropriee au patient souffrant de polymorphisme fc$g(g)riiia
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
US7749753B2 (en) 2002-04-09 2010-07-06 Kyowa Hakko Kirin Co., Ltd Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost
CA2481657A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
AU2003235256A1 (en) 2002-04-19 2003-11-03 Kyowa Hakko Kogyo Co., Ltd. Phenylalanine derivative
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
US20030219818A1 (en) 2002-05-10 2003-11-27 Bohen Sean P. Methods and compositions for determining neoplastic disease responsiveness to antibody therapy
EP1575514A2 (en) 2002-07-31 2005-09-21 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
DK3284753T3 (da) 2002-10-17 2021-07-05 Genmab As Humane monoklonale antistoffer mod cd20 til anvendelse i behandlingen af multipel sclerose
EP1572744B1 (en) 2002-12-16 2010-06-09 Genentech, Inc. Immunoglobulin variants and uses thereof
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP2062916A3 (en) * 2003-04-09 2009-08-19 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitor
JP2006523735A (ja) 2003-04-18 2006-10-19 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 抗菌顔料
NZ568403A (en) 2003-05-09 2009-10-30 Univ Duke CD20-specific antibodies and methods of employing same
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
EP1494122B8 (en) 2003-07-02 2007-06-06 Seiko Epson Corporation A data transferring apparatus for transferring liquid ejection data and a liquid ejecting apparatus
WO2005014618A2 (en) 2003-08-08 2005-02-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
CA2542046A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Fused protein composition
EP1705251A4 (en) 2003-10-09 2009-10-28 Kyowa Hakko Kirin Co Ltd PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE
ME01775B (me) 2003-11-05 2011-02-28 Glycart Biotechnology Ag Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
BRPI0417105A (pt) * 2003-12-19 2007-02-06 Genentech Inc métodos de tratamento de doenças autoimunológicas em pacientes
UA86605C2 (ru) 2004-01-12 2009-05-12 Аплайд Молекьюлер Иволюшн, Инк. Антитело, которое содержит вариант исходного человеческого fс-участка
US7850962B2 (en) * 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US7630892B2 (en) 2004-09-10 2009-12-08 Microsoft Corporation Method and apparatus for transducer-based text normalization and inverse text normalization
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
BRPI0811732A2 (pt) 2007-06-08 2014-11-18 Boehring Ingelheim Internat Gmbh Formulação de liberação prolongada de nevirapina

Also Published As

Publication number Publication date
MY162988A (en) 2017-07-31
JP2013056945A (ja) 2013-03-28
US20190270824A1 (en) 2019-09-05
US20210024643A1 (en) 2021-01-28
AU2006315498A1 (en) 2007-05-24
CN101365487B (zh) 2013-04-17
JP2009515979A (ja) 2009-04-16
RU2457860C2 (ru) 2012-08-10
CA2783210C (en) 2016-10-04
EP1951304B1 (en) 2014-10-22
TW200735889A (en) 2007-10-01
IL191118B (en) 2018-08-30
MA30047B1 (fr) 2008-12-01
SI1951304T1 (sl) 2015-02-27
RU2008123794A (ru) 2009-12-27
US20160176974A1 (en) 2016-06-23
UA94726C2 (ru) 2011-06-10
MX2008006113A (es) 2008-05-31
US20090238762A1 (en) 2009-09-24
RS53767B1 (en) 2015-06-30
PL1951304T3 (pl) 2015-03-31
HRP20150018T1 (hr) 2015-03-27
DK1951304T3 (en) 2014-11-24
KR20080105025A (ko) 2008-12-03
MY149159A (en) 2013-07-31
TWI380826B (zh) 2013-01-01
ZA200804288B (en) 2010-10-27
AU2006315498B2 (en) 2012-08-16
JP2014218518A (ja) 2014-11-20
ECSP088514A (es) 2008-10-31
JP2017039775A (ja) 2017-02-23
US10654940B2 (en) 2020-05-19
NO20082658L (no) 2008-08-15
IL191118A0 (en) 2008-12-29
US20190382501A1 (en) 2019-12-19
JP6132443B2 (ja) 2017-05-24
NZ567709A (en) 2011-07-29
KR20150105493A (ko) 2015-09-16
CA2627886A1 (en) 2007-05-24
WO2007059188A1 (en) 2007-05-24
PT1951304E (pt) 2015-01-02
ES2526616T3 (es) 2015-01-13
KR20180056797A (ko) 2018-05-29
AR058838A1 (es) 2008-02-27
HK1128004A1 (en) 2009-10-16
BRPI0618577A2 (pt) 2011-09-06
US10450379B2 (en) 2019-10-22
EP1951304A1 (en) 2008-08-06
CN101365487A (zh) 2009-02-11
CR10005A (es) 2008-09-22
KR20140099927A (ko) 2014-08-13
CN103212070A (zh) 2013-07-24
KR20190009425A (ko) 2019-01-28
CA2783210A1 (en) 2007-05-24
CA2627886C (en) 2019-01-08
HK1123209A1 (en) 2009-06-12

Similar Documents

Publication Publication Date Title
BRPI0618577A8 (pt) Usos de rituximab
AR088289A1 (es) Composiciones para el tratamiento de la artritis reumatoide y metodos para su utilizacion
BR112013030597A2 (pt) método e aparelho (1) para fabricação de estruturas absorventes com material absorvente
CL2011002943A1 (es) Anticuerpo triespecifico o tetraespecifico; metodo para la preparacion de dicho anticuerpo; celula huesped; composicion farmaceutica.
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
BRPI0906478B8 (pt) anticorpo anti-nr10, seu uso e composição farmacêutica que o compreende
BR112013002484A2 (pt) composto, composição farmacêutica, métodos para tratar esclerose múltipla e artrite reumatoide, e, uso de um composto.
CL2011000527A1 (es) Compuestos derivados de benzofurano; composicion farmaceutica que los comprende;y su uso en el tratamiento de la hepatitis c.
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
CL2010001637A1 (es) Compuestos derivados de isoindolonas; composición farmacéutica que los comprende; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas y/o inflamatorias tales como cáncer, artritis reumatoidea entre otras.
BR112014029099A2 (pt) anticorpos anti-egfr e seu uso para inibir ou atenuar crescimento de tumor, bem como composição farmacêutica que o compreende
BR112015023001A2 (pt) composição de salto de exon para tratamento de distrofia muscular
CL2012001627A1 (es) Compuestos derivados de 1,3-tiazol-fenilaminopirimidinas, inhibidores de syk; composición farmacéutica; y su uso para el tratamiento de la artritis reumatoide y cancer.
BR112012018132A2 (pt) "marcadores de células - tronco tumorais e uso dos mesmos".
BR112015023648A2 (pt) revestimento de superfície reativo com propriedades de descontaminação química e biocidas
BR112012008282A2 (pt) anticorpos de neutralização anti-nfg humanos como inibidores de curso de ngf seletivos
PA8840801A1 (es) Derivaos de dioxa-biciclo[3.2.1]octano-2,3,4-triol
CL2013000100A1 (es) Composicion que comprende un agente de contraste para rayos x yodado y un portador o excipiente farmaceuticamente aceptable, donde la concentracion de yodo es de 10-170 mgl/ml; un metodo de examen con rayos x que comprende el uso de la composicion.
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
CL2007003423A1 (es) Compuestos derivados de pirimidinas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de artritis reumatoidea, aterosclerosis, entre otras enfermeda
CY1123240T1 (el) Αντισωμα αντι fgf23 και μια φαρμακευτικη συνθεση που το περιλαμβανει
CL2015001279A1 (es) Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras.
BR112012018843B8 (pt) radioimunoconjugado que se liga a cd37 humano, composição farmacêutica e kit para a produção do radioimunoconjugado
GT200800187A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
BR112012023660B8 (pt) usos de uma quantidade terapeuticamente eficaz de um composto, ou de um sal, solvato, hidrato ou pró-fármaco farmaceuticamente aceitável do mesmo para o tratamento de câncer

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: APRESENTE DOCUMENTOS COMPROBATORIOS DA ALTERACAO NO QUADRO DO DEPOSITANTE REALIZADO ATRAVES DA PETICAO NO 020080097604/NPRJ DE 14/07/2008 DIVERGINDO DA PUBLICACAO WO2007/059188 DE 24/05/2007.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2153 DE 10/04/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B25D Requested change of name of applicant approved

Owner name: GENENTECH, INC. (US) , F. HOFFMANN-LA ROCHE AG (CH

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2493 DE 16-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.